PatientsVille.com Logo


Lymphopenia Medical Research Studies

Up-to-date List of Lymphopenia Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Lymphopenia Medical Research Studies

Rank Status Study
1 Recruiting Idiopathic CD4 Lymphocytopenia
Condition: Idiopathic CD4 Lymphocytopenia
Interventions: Biological: Constitution of a biobank of frozen cells, plasma and serum samples;   Genetic: Genetic study
Outcome Measures: Idiopathic CD4+ T lymphocytopenia Diagnosis;   Clinical, immunological and follow up characteristics of all patients;   Response to IL-2 or IL-7 treatment;   Incident cases of ICL in first degree relatives;   Thymic volume and correlation with CD4+ level;   Analysis of differentiation and activation of T and B lymphocytes
2 Recruiting Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Conditions: Idiopathic CD4+ Lymphocytopenia;   Cryptococcal Meningitis;   Warts
Outcome Measure:
3 Recruiting Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia
Condition: Malignant Neoplasms Brain
Interventions: Biological: RNA-loaded dendritic cell vaccine;   Drug: basiliximab
Outcome Measures: Functional capacity of CD4+,CD25+, CD127- T-regulatory cells;   Safety
4 Recruiting Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Condition: T-Lymphocytopenia, Idiopathic CD4-Positive
Outcome Measure: to assess peripheral CD4 T cell and CD34 plus hematopoietic progenitor cell numbers and functions in ICL patients compared to controls following G-CSF and plerixafor administration.
5 Recruiting Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Conditions: Graft vs Host Disease;   Healthy;   Lymphopenia
Intervention: Drug: G-CSF
Outcome Measure: Enumeration of laboratory studies using collected primitive hematopoietic cells and immune effector cells.
6 Recruiting Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant
Conditions: Anemia;   Hematopoietic/Lymphoid Cancer;   Lymphopenia;   Neutropenia;   Thrombocytopenia
Interventions: Biological: Allogeneic hematopoietic stem cell transplantation;   Biological: Peripheral blood stem cell transplantation;   Procedure: Management of therapy complications
Outcome Measures: Etiologies of post HSCT cytopenias;   CD34+/kg and CD3+/kg cell doses in the infused CD 34+ selected boost products;   Effects of the CD 34+ selected boost on peripheral blood cell counts;   Incidence of GVHD related to the CD34+ selected boost;   Incidence of grade 3-5 infusion reactions, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0;   Incidence of severe GVHD (grades 3-4), graded according to standard criteria
7 Recruiting Evaluation and Follow-up of Patients With Cryptococcosis
Conditions: Cryptococcosis;   Lymphopenia
Outcome Measure:
8 Recruiting Natural History Study of GATA2 Deficiency and Related Disorders
Conditions: Myelodysplasia;   Monocytopenia;   B Cell Lymphopenia;   NK Cell Deficiency;   Warts
Outcome Measure: This natural history protocol is designed to further characterize the clinical phenotype of GATA2 deficiency,
9 Recruiting Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Condition: Multiple Sclerosis
Intervention: Drug: Cladribine
Outcome Measures: Number of subjects with serious adverse drug reactions (SADRs);   Time to resolution of Lymphopenia, among registry participants with persistent Lymphopenia;   Number of subjects with all Adverse Events (AEs) in the "Blood and Lymphatic System Disorders" System Organ Class (SOC) and in the "Neoplasms Benign, Malignant, and Unspecified" SOC;   Pregnancy outcomes
10 Not yet recruiting Immunologic Responses in HPV-Associated Carcinoma for Patients Receiving Chemoradiation
Conditions: Head and Neck Cancer;   HPV (Human Papillomavirus)-Associated Carcinoma;   Oropharyngeal
Intervention: Other: research blood draw and tissue biopsy
Outcome Measures: Compare Systemic and Local Immunologic Changes During Chemoradiation;   Relationship of Radiotherapy-Related Lymphopenia and Changes in Cellular Immunity During Chemoradiation
11 Recruiting Reduced Intensity Conditioning in Patients Aged ≤30 With Non-Malignant Disorders Undergoing Cord Blood Transplantation
Conditions: Primary Immunodeficiency Syndromes;   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Patients With Sickle Disease Presenting Specific Symptoms
Interventions: Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa
Outcome Measures: Post-transplant treatment-related mortality (TRM);   Neurodevelopmental milestones;   Immune Reconstitution;   Severe opportunistic infections;   GVHD occurrence;   Donor cell engraftment;   Normal enzyme level;   Neutrophil recovery;   Platelet recovery;   Grade 3-4 organ toxicity;   Long-term complications;   Late graft failure
12 Unknown  Secondary Adult's Hemophagocytic Lymphohistiocytosis and Innate Immunity
Condition: Hemophagocytic Lymphohisticytosis
Intervention: Other: blood sample
Outcome Measures: the cytotoxicité lymphocytaire;   Study of the mechanisms of the activation macrophagique
13 Recruiting EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Paclitaxel + Carboplatin every 3 weeks;   Drug: Carboplatin monotherapy every 3 weeks;   Drug: Weekly Paclitaxel and Carboplatin
Outcome Measures: Treatment success.Treatment success is defined as the ability to deliver 6 courses of chemotherapy without premature termination for progression, death or unacceptable toxicity;   Therapeutical strategy;   Overall Survival;   Progression-free survival;   Quality of Life;   Safety and tolerability;   Aging biomarkers
14 Recruiting Abatacept Reduced Intensity for Non-Malignant Diseases
Conditions: Hurler Syndrome;   Fanconi Anemia;   Glanzmann Thrombasthenia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   Severe Congenital Neutropenia;   Leukocyte Adhesion Deficiency;   Shwachman Diamond Syndrome;   Diamond Blackfan Anemia;   Dyskeratosis Congenita;   Chediak Higashi Syndrome;   Severe Aplastic Anemia;   Thalassemia;   Hemophagocytic Lymphohistiocytosis
Interventions: Drug: 4 doses of abatacept;   Drug: 6 doses of abatacept
Outcome Measures: Tolerability of abatacept;   Immunological effects
15 Unknown  Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells
Conditions: Sickle Cell Disease;   Thalassemia;   Anemia;   Granuloma;   Wiskott-Aldrich Syndrome;   Chediak Higashi Syndrome;   Osteopetrosis;   Neutropenia;   Thrombocytopenia;   Hurler Disease;   Niemann-Pick Disease;   Fucosidosis
Intervention: Procedure: Hematopoietic stem cell transplantation
Outcome Measures: toxicities;   adverse events;   engraftment;   immune reconstitution;   overall and event free survival survival
16 Recruiting Participation in a Research Registry for Immune Disorders
Conditions: ADA-SCID;   Adenosine Deaminase Deficiency;   Wiskott- Aldrich Syndrome;   Primary Immunodeficiencies;   Severe Combined Immune Deficiency
Outcome Measure: We will add NHGRI patients enrolled in 00-HG-0209 into a national registry of individuals with primary immune deficiency disorders to discover basic outcome data, ethnic and racial characteristics, kinds of complications etc. of these immune def...
17 Recruiting Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome
Condition: Wiskott-Aldrich Syndrome
Intervention: Biological: Retrovirus-mediated gene transfer
Outcome Measures: Safety of infusion of transduced cells;   Engraftment of genetically corrected T cells
18 Recruiting Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Aplastic Anemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Congenital Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Paroxysmal Nocturnal Hemoglobinuria;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Severe Combined Immunodeficiency;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
Interventions: Drug: fludarabine phosphate;   Drug: melphalan;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Drug: methotrexate;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Outcome Measure: transplant related mortality (TRM) for patients undergoing RIT with co-morbidities or who are otherwise not eligible or unable to receive a myeloablative allogeneic HSCT
19 Not yet recruiting Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990
Condition: Wiskott-Aldrich Syndrome
Outcome Measures: Longitudinal Analysis: Overall Survival From Time of HCT/Gene Therapy;   Cross-Sectional Analysis: Proportion of Participants Achieving Full T Cell Reconstitution;   Cross-Sectional Analysis: Proportion of Participants Achieving Full B Cell Reconstitution;   Cross-Sectional Analysis: Proportion of Participants Achieving Resolution of thrombocytopenia;   Cross-Sectional Analysis: Day of Recovery of Absolute Neutrophil Count (ANC) to 500 / uL;   Cross-sectional Analysis: Day of Recovery of Platelet Count to 20,000 / uL;   Cross-sectional Analysis: Day of Recovery of Platelet Count to 50,000 / uL;   Longitudinal Analysis: Proportion of Participants Achieving Hematologic Reconstitution;   Longitudinal Analysis: Day of Recovery of Absolute Neutrophil Count (ANC) to 500 / uL;   Longitudinal Analysis: Day of Recovery of Platelet Count to 20,000 / uL;   Longitudinal Analysis: Day of Recovery of Platelet Count to 50,000 / uL;   Longitudinal Analysis: Proportion of Participants Achieving Full T Cell Immune Reconstitution;   Longitudinal Analysis: Proportion of Participants Achieving Full B Cell Immune Reconstitution;   Longitudinal Analysis: State of Lineage Specific Chimerism (HCT Stratum);   Longitudinal Analysis: Definition of Graft Failure / Rejection;   Longitudinal Analysis: Severe bleeding episodes;   Longitudinal Analysis: Malignancy;   Longitudinal Analysis: Growth;   Longitudinal Analysis: Incidence of Acute GVHD;   Longitudinal Analysis: Incidence of Chronic GVHD;   Longitudinal Analysis: Autoimmunity disorders;   Longitudinal Analysis: Infections / blood borne infections;   Cross-sectional Analysis: Current State of Lineage Specific Chimerism (HCT Stratum);   Cross-sectional Analysis: Current frequency and severity of infections;   Cross-sectional Analysis: Current Status of Growth;   Cross-Sectional Analysis: Graft-versus-host Disease (GvHD);   Cross-Sectional Analysis: Autoimmunity Disorders;   Cross-sectional Analysis: Severe Bleeding Episodes;   Cross-sectional Analysis: fertility;   Cross-sectional Analysis: malignancy;   Cross-sectional Analysis: Quality of Life Questionnaire
20 Unknown  Gene Therapy for Wiskott-Aldrich Syndrome (WAS)
Condition: Wiskott-Aldrich Syndrome
Intervention: Biological: ex vivo gene therapy
Outcome Measures: number of patients safely receiving the conditioning regimen;   number of patients whose stem cells are safely transduced;   number of patients with engraftment of genetically corrected hematopoietic progenitors/differentiated cells;   number of patients with reconstituted cell mediated and humoral immunity;   number of patients with corrected microthrombocytopenia;   number of patients with reduced frequency of infection;   number of patients with resolution/reduction of autoimmunity;   number of patients with improvement in eczema;   number of patients with reduction in bruising and bleeding episodes

These studies may lead to new treatments and are adding insight into Lymphopenia etiology and treatment.

A major focus of Lymphopenia research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Lymphopenia